FOCUS ON INNOVATION: WORKING WITH YOU TO CLOSE THE LOOP IN DIABETES EDUCATION
LETTER FROM THE MEDTRONIC DIABETES CMO
FOCUS ON INNOVATION:
WORKING WITH YOU TO CLOSE THE LOOP IN DIABETES EDUCATION
BY FRANCINE RATNER KAUFMAN, MDAt Medtronic Diabetes, we focus every day on advancing technology, with the ultimate goal of “closing the loop” for patients with type 1 and type 2 diabetes. With every innovation, we move a step closer to that goal. Recently, we were thrilled to learn that others are recognizing our progress. The current update to the Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force refers specifically to the MiniMed® 530G with Enlite®, stating: “FDA recently approved a [sensor-augmented pump system] that represents the first step toward an automatic or semiautomatic closed-loop insulin delivery device.”
TODAY’S INNOVATION, TOMORROW’S PATIENT CAREAs with patient education, innovations in technology are evolutionary. Medtronic Diabetes’ leadership in diabetes management and products spans more than 30 years. During that time, we have achieved a number of milestones:
- In 1983, we introduced the first MiniMed insulin pump.
- In 2006, we broke new ground by introducing the first integrated personal continuous glucose monitoring (CGM) and therapy management system.
- And in 2013, Medtronic’s MiniMed 530G with Enlite, which mimics some of the functionality of a healthy pancreas, became the first—and so far the only—approved device in the Food and Drug Administration’s new artificial pancreas device system (APDS) category.
INNOVATION IN EDUCATIONNo one knows better than you the importance that diabetes education holds in the optimal treatment of insulin-dependent diabetes. Innovations in education are just as critical as advances in technology. When we speak of closing the loop in diabetes care, we of course mean in the clinical sense. However, that same concept can apply to diabetes education. By working together and partnering with you and your patients in their lifelong journey of diabetes control, we also can close the loop in diabetes education. Along with our colleagues at Bayer HealthCare, Medtronic Diabetes has created In the Know as a step toward that goal. As with patient care, you are at the center of this effort. We may have launched this newsletter, but we want you to think of it as yours: A place where you can share information and best practices, successes and struggles, tips and tricks. Greater innovation always comes from collaboration, which benefits everyone involved—especially patients.
Grunberger G, Abelseth JM, Bailey TS, et al. Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force. Endocr Pract. 2014;20(5):463-489. Available at: https://www.aace.com/files/insulin-pump-management-cs.pdf. Accessed April 22, 2015.